Neuroprotection by caffeine in the MPTP model of parkinson’s disease and its dependence on adenosine A2A receptors
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Considerable epidemiological and laboratory data have suggested that caffeine, a nonselective adenosine receptor antagonist, may protect against the underlying neurodegeneration of Parkinson’s disease (PD). Although both caffeine and more specific antagonists of the A2A subtype of adenosine receptor (A2AR) have been found to confer protection in animal models of PD, the dependence of caffeine’s neuroprotective effects on the A2AR is not known. To definitively determine its A2AR dependence, the effect of caffeine on MPTP neurotoxicity was compared in wild-type (WT) and A2AR gene global knockout (A2A KO) mice, as well as in CNS cell type-specific (conditional) A2AR knockout (cKO) mice that lack the receptor either in postnatal forebrain neurons or in astrocytes. In WT and in heterozygous A2AR KO mice caffeine pretreatment (25 mg/kg ip) significantly attenuated MPTP-induced depletion of striatal dopamine. By contrast in homozygous A2AR global KO mice caffeine had no effect on MPTP toxicity. In forebrain neuron A2AR cKO mice, caffeine lost its locomotor stimulant effect, whereas its neuroprotective effect was mostly preserved. In astrocytic A2AR cKO mice, both caffeine’s locomotor stimulant and protective properties were undiminished. Taken together, these results indicate that neuroprotection by caffeine in the MPTP model of PD relies on the A2AR, although the specific cellular localization of these receptors remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 3×
“Although caffeinated coffee, tea and soda comprise many chemical constituents, the finding that regular but not decaffeinated coffee consumption is predictive of reduced PD risk (Ascherio et al., 2001; Palacios et al., 2012) implicates caffeine as the basis of the inverse association.”
BackgroundStevens (2002) · doi:10.1016/s0896-6273(02)01067-x · Cited by 543
An Update on the Mechanisms of the Psychostimulant Effects of Caffeine
Ferré, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05196.x · Cited by 440 · cited 1×
“Several studies have indicated that caffeine exerts its psychostimulant effects acting as a nonselective adenosine A1R and A2AR receptor antagonist (Fredholm and Persson, 1982; Nehlig et al., 1992; Fredholm and Lindström, 1999; Fisone et al., 2004; Ferré, 2008).”
BackgroundAscherio, A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh312 · Cited by 232 · cited 1×
“Multiple epidemiological studies have also shown that people who consume more caffeinated beverages are substantially less likely to develop PD (Ross et al., 2000, Ascherio et al., 2001, 2004).”
BackgroundCaffeine and risk of Parkinson’s disease in a large cohort of men and women
Palacios, N., Gao, X., McCullough, M. L., Schwarzschild, M. A., Shah, R., Gapstur, S., & Ascherio, A. (2012) · Movement Disorders · doi:10.1002/mds.25076 · Cited by 185 · cited 1×
“Although caffeinated coffee, tea and soda comprise many chemical constituents, the finding that regular but not decaffeinated coffee consumption is predictive of reduced PD risk (Ascherio et al., 2001; Palacios et al., 2012) implicates caffeine as the basis of the inverse association.”
BackgroundSelf-citationMatos, M., Shen, H.-Y., Augusto, E., Wang, Y., Wei, C. J., Wang, Y. T., Agostinho, P., Boison, D., Cunha, R. A., & Chen, J.-F. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.026 · Cited by 153 · cited 2×
“Breeding and characterization of global A2AR knockout mice (A2A KO), CaMKIIα gene promoter-driven forebrain neuron A2AR cKO mice (CaMKIIα-A2AR KO) as well as the GFAP gene promoter-driven astrocyte A2AR cKO (gfap-A2AR KO) mice have been described previously (Chen et al., 1999, 2002; Bastia et al., 2005; Yu et al., 200…”
MethodSelf-citation
Cited by
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
van Dam, R. M., Hu, F. B., & Willett, W. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1816604 · Cited by 508
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Manalo, R. V. M., & Medina, P. M. B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00137 · Cited by 55
Chen, J.-F., & Schwarzschild, M. A. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.024 · Cited by 39
Self-citation
Metadata
- Authors
- Xu, K., Di Luca, D. G., Orrú, M., Xu, Y., Chen, J.-F., & Schwarzschild, M. A.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 322
- Pages
- 129-137
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2283842224
- Cited by
- 83
- References
- 7
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotection by caffeine in the MPTP model of parkinson’s disease and its dependence on adenosine A2A receptors. https://app.cochat.ai/papers/10.1016/j.neuroscience.2016.02.035
- The paper
- Xu, K., Di Luca, D. G., Orrú, M., Xu, Y., Chen, J.-F., & Schwarzschild, M. A. (2016). Neuroprotection by caffeine in the MPTP model of parkinson’s disease and its dependence on adenosine A2A receptors. Neuroscience. https://doi.org/10.1016/j.neuroscience.2016.02.035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.